USFDA  Approves Aurobindo Pharma's Vecuronium Bromide Injection

| December 24 , 2018 , 12:24 IST

US Food & Drug Administration(USFDA) on Monday finally allowed Aurobindo Pharma to produce and sale Vecuronium Bromide Injection, 10mg and 20mg.

Aurobindo’s Vecuronium Bromide Injection is a generic equivalent of Organon’s Norcuron Injection.

The product will be launched in Q4FY19, as per the company's BSE filing.

Vecuronium Bromide Injection is used as part of general anaesthesia to provide skeletal muscle relaxation during surgery or mechanical ventilation.

It is also used to facilitate endotracheal intubation.

The approved product has an estimated market size of $11mn for the twelve months ending September 2018, according to IQVIA.

This is the 58th ANDA to be approved out of the Unit IV formulation facility in Hyderabad used for manufacturing general injectable & ophthalmic products.

Aurobindo now has a total of 397 ANDA approvals (369 Final approvals including 20 from Aurolife Pharma LLC and 28 tentative approvals) from USFDA.

Aurobindo Pharma Ltd is currently trading at Rs725.20 up by Rs4.65 or 0.65% from its previous closing of Rs720.55 on the BSE.

ALSO READ: Aurobindo May Launch Tramadol Tablets In US Market

Aurobindo Pharma is a pharmaceutical manufacturing company headquartered in HITEC city, Hyderabad, India.

The company manufactures generic pharmaceuticals and active pharmaceutical ingredients.

The company’s area of activity includes six major therapeutic/product areas: antibiotics, antiretrovirals, cardiovascular products, central nervous system products, gastroenterological, and anti-allergic.

The company markets these products in over 125 countries. Its marketing partners include AstraZeneca and Pfizer.